Login / Signup

Anticonvulsant effect of equilibrative nucleoside transporters 1 inhibitor in a mouse model of Dravet syndrome.

Shih-Yin HoI-Chun ChenChe-Wen TsaiKai-Chieh ChangChun-Jung LinYijuang ChernHorng-Huei Liou
Published in: Hippocampus (2023)
There are limited therapeutic options for patients with Dravet syndrome (DS). The equilibrative nucleoside transporters 1 (ENT1) mediate both the influx and efflux of adenosine across the cell membrane exerted beneficial effects in the treatment of epilepsy. This study aimed to evaluate the anticonvulsant effect of the ENT1 inhibitor in an animal model of DS (Scn1a E1099X/+ mice). J7 (5 mg/kg) treatment was efficacious in elevating seizure threshold in Scn1a E1099X/+ mice after hyperthermia exposure. Moreover, the J7 treatment significantly reduced the frequency of spontaneous excitatory post-synaptic currents (sEPSCs, ~35% reduction) without affecting the amplitude in dentate gyrus (DG) granule cells. Pretreatment with the adenosine A1 receptor (A1R) antagonist, DPCPX, abolished the J7 effects on sEPSCs. These observations suggest that the J7 shows an anticonvulsant effect in hyperthermia-induced seizures in Scn1a E1099X/+ mice. This effect possibly acts on presynaptic A1R-mediated signaling modulation in granule cells.
Keyphrases
  • mouse model
  • induced apoptosis
  • case report
  • type diabetes
  • adipose tissue
  • metabolic syndrome
  • diabetic rats
  • high glucose